Mirum Pharma CEO Christopher Peetz Has Sold $10.4M — MIRM Stock Up 4x From His Exercise Prices
Mirum Pharmaceuticals CEO Christopher Peetz sold $10.4M across 81 transactions, exercising options as low as $2.94 and selling at $55-$103/share as MIRM stock surged on Livmarli success.
Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), has sold $10.4 million across 81 insider transactions. His February 2026 sale of 9,108 shares at $103.30 marks the highest price in his selling history — a 35x return on options originally granted at $2.94/share.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $10.4M |
| Career Buy Value | $314K |
| Total Transactions | 81 |
| Last Transaction | 2026-02-02 |
| Shares Remaining | 160,294 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-02-02 | Sell | 9,108 | $103.3035 | $941K |
| 2025-11-18 | Exercise | 19,133 | N/A | $0 |
| 2025-11-18 | Exercise | 19,133 | $19.2400 | $368K |
| 2025-08-11 | Sell | 40,000 | $62.0000 | $2.5M |
Peetz's selling accelerated in 2025 as MIRM surged on Livmarli's commercial success: $2.2M at $55 in August, $2.5M at $62 in August, and $941K at $103 in February 2026. The exercise-and-sell pattern shows him converting deep-in-the-money options into cash as the stock price rises, a common pattern for biotech CEOs whose companies transition from clinical to commercial stage.
What It Means
The spread between Peetz's exercise prices ($2.94-$19.24) and selling prices ($55-$103) represents the value creation journey of a successful biotech: from pre-approval uncertainty to commercial-stage validation. His $10.4M in career sales came almost entirely in 2025-2026 as Livmarli's launch in cholestatic liver diseases drove MIRM from ~$30 to $100+.
With 160,294 shares remaining (~$16.5M at current prices), Peetz's retained position exceeds his career sales — a positive alignment signal for MIRM investors. The CEO is monetizing some of his paper gains while maintaining a larger bet on the company's pipeline expansion beyond Livmarli. His $314K in career purchases shows he also bought stock at earlier, lower prices.
What to Watch
- Whether Peetz continues selling as MIRM trades above $100
- Livmarli prescription volume trends and payer coverage expansion
- Mirum's pipeline readouts beyond Livmarli for additional indications
- Other MIRM insiders' selling activity at these elevated levels
Breaking News Editor at 13F Insight. First to report on major SEC filings, institutional moves, and regulatory developments.
More from Alex →